Purpose of Review
Recent evidence has shown an overwhelming benefit of mechanical thrombectomy for acute anterior circulation large vessel occlusion (LVO). Whether there is any additional benefit of IV tPA treatment prior to thrombectomy over thrombectomy alone is unproven in randomized trials. In this review, we summarize the available evidence for and against pre-thrombectomy treatment with IV tPA.
In clinical trials demonstrating efficacy of thrombectomy, the majority of included patients were eligible for (and treated with) IV tPA. Systemic thrombolysis prior to thrombectomy is fraught with potential disadvantages: delay in thrombectomy, increased risk of systemic hemorrhagic complications and angioedema, and limitation of endovascular treatment options in patients who require more vigorous antithrombotic treatment (for instance due to stent placement). Two randomized clinical trials comparing outcomes of patients treated with IV tPA + thrombectomy versus thrombectomy alone have recently reported their outcomes. The DIRECT-MT investigators found no difference in functional outcomes or mortality among patients pre-treated with IV tPA prior to thrombectomy, while the SKIP investigators found similar rates of good functional outcome and mortality between treatment groups--although they failed to demonstrate non-inferiority. The limitations of these trials are reviewed here. Therefore, much of our understanding relies on indirect comparisons between patient groups, whereby patients treated with IV tPA + thrombectomy were compared with IV tPA-ineligible patients who underwent thrombectomy alone. Limited meta-analysis data suggest equipoise between combination therapy over a direct-to-thrombectomy approach for patients with acute LVO who meet criteria for IV tPA. Further confounding the picture is the emergence of IV tenecteplase as a potentially superior alternative to alteplase as a pre-thrombectomy systemic lytic agent in patients with LVO.
While thrombectomy offers a more effective means of reperfusion in acute LVO compared with IV tPA alone, definitive evidence is lacking that thrombectomy without prior IV thrombolysis is equivalent (or superior) to thrombectomy preceded by IV tPA. While recent trial evidence has suggested non-inferiority of direct MT, given that IV thrombolysis has been established as a standard of care in acute ischemic stroke, IV tPA should be given in all eligible patients with disabling deficits for whom thrombectomy is not immediately available. Results of further, ongoing randomized trials will hopefully clarify what (if any) additional benefit there is for intravenous thrombolysis prior to thrombectomy, in what subgroups (if any) withholding IV thrombolysis prior to MT is beneficial, and furthermore, which agent (alteplase or tenecteplase) is the optimal drug for this indication.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
References and Recommended Reading
Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40:2079–84.
Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA : the journal of the American Medical Association. 1995;274:1017–25.
National Institute of Neurological D and Stroke rt PASSG. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.
Menon BK, Al-Ajlan FS, Najm M, Puig J, Castellanos M, Dowlatshahi D, et al. Association of clinical, imaging, and thrombus characteristics with recanalization of visible intracranial occlusion in patients with acute ischemic stroke. JAMA : the journal of the American Medical Association. 2018;320:1017–26.
Alexandrov AV, Burgin WS, Demchuk AM, El-Mitwalli A, Grotta JC. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. Circulation. 2001;103:2897–902.
Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38:948–54.
Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723–31.
Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708–18.
Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378:11–21.
Kaesmacher J, Mordasini P, Arnold M, Lopez-Cancio E, Cerda N, Boeckh-Behrens T, et al. Direct mechanical thrombectomy in tPA-ineligible and -eligible patients versus the bridging approach: a meta-analysis. J Neurointerv Surg. 2019;11:20–7.
Mair G, von Kummer R, Adami A, White PM, Adams ME, Yan B, et al. Arterial obstruction on computed tomographic or magnetic resonance angiography and response to intravenous thrombolytics in ischemic stroke. Stroke. 2017;48:353–60.
Christou I, Felberg RA, Demchuk AM, Burgin WS, Malkoff M, Grotta JC, et al. Intravenous tissue plasminogen activator and flow improvement in acute ischemic stroke patients with internal carotid artery occlusion. J Neuroimaging. 2002;12:119–23.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344–418.
Yang P, Zhang Y, Zhang L, Zhang Y, Treurniet KM, Chen W, et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke. N Engl J Med. 2020.
Suzuki K, Matsumaru Y, Takeuchi M, Morimoto M, Higashida T, Takayama Y, et al. The randomized study of endovascular therapy with versus without intravenous tissue plasminogen activator in acute stroke with ICA and M1 occlusion (SKIP study). Available online at https://www.professional.heart.org/professional/ScienceNews/UCM_505646_SKIP-Study-Clinical-Trial-Details.jsp. Presented Feb 21, 2020. International Stroke Conference. Accessed 22 June 2020.
Katsanos AH, Tsivgoulis G. Is intravenous thrombolysis still necessary in patients who undergo mechanical thrombectomy? Curr Opin Neurol. 2019;32:3–12.
Tsivgoulis G, Zand R, Katsanos AH, Turc G, Nolte CH, Jung S, et al. Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden: a meta-analysis. JAMA Neurol. 2016;73:675–83.
Arca KN, Demaerschalk BM, Almader-Douglas D, Wingerchuk DM, O'Carroll CB. Does high cerebral microbleed burden increase the risk of intracerebral hemorrhage after intravenous tissue plasminogen activator for acute ischemic stroke? Neurologist. 2019;24:40–3.
Froehler MT, Saver JL, Zaidat OO, Jahan R, Aziz-Sultan MA, Klucznik RP, et al. Interhospital transfer before thrombectomy is associated with delayed treatment and worse outcome in the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke). Circulation. 2017;136:2311–21.
Gariel F, Lapergue B, Bourcier R, Berge J, Barreau X, Mazighi M, et al. Mechanical thrombectomy outcomes with or without intravenous thrombolysis. Stroke. 2018;49:2383–90.
Alonso de Lecinana M, Martinez-Sanchez P, Garcia-Pastor A, Kawiorski MM, Calleja P, Sanz-Cuesta BE, et al. Mechanical thrombectomy in patients with medical contraindications for intravenous thrombolysis: a prospective observational study. J Neurointerv Surg. 2017;9:1041–6.
Guedin P, Larcher A, Decroix JP, Labreuche J, Dreyfus JF, Evrard S, et al. Prior IV thrombolysis facilitates mechanical thrombectomy in acute ischemic stroke. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2015;24:952–7.
Kaesmacher J, Kleine JF. Bridging therapy with i. v. rtPA in MCA occlusion prior to endovascular thrombectomy: a double-edged sword? Clin Neuroradiol. 2018;28:81–9.
Maier IL, Behme D, Schnieder M, Tsogkas I, Schregel K, Kleinknecht A, et al. Bridging-therapy with intravenous recombinant tissue plasminogen activator improves functional outcome in patients with endovascular treatment in acute stroke. J Neurol Sci. 2017;372:300–4.
Merlino G, Sponza M, Petralia B, Vit A, Gavrilovic V, Pellegrin A, et al. Short and long-term outcomes after combined intravenous thrombolysis and mechanical thrombectomy versus direct mechanical thrombectomy: a prospective single-center study. J Thromb Thrombolysis. 2017;44:203–9.
Rai AT, Boo S, Buseman C, Adcock AK, Tarabishy AR, Miller MM, et al. Intravenous thrombolysis before endovascular therapy for large vessel strokes can lead to significantly higher hospital costs without improving outcomes. J Neurointerv Surg. 2018;10:17–21.
Wee CK, McAuliffe W, Phatouros CC, Phillips TJ, Blacker D, Singh TP, et al. Outcomes of endovascular thrombectomy with and without thrombolysis for acute large artery ischaemic stroke at a tertiary stroke centre. Cerebrovasc Dis Extra. 2017;7:95–102.
Coutinho JM, Liebeskind DS, Slater LA, Nogueira RG, Clark W, Davalos A, et al. Combined intravenous thrombolysis and thrombectomy vs thrombectomy alone for acute ischemic stroke: a pooled analysis of the SWIFT and STAR studies. JAMA Neurol. 2017;74:268–74.
Ferrigno M, Bricout N, Leys D, Estrade L, Cordonnier C, Personnic T, et al. Intravenous recombinant tissue-type plasminogen activator: influence on outcome in anterior circulation ischemic stroke treated by mechanical thrombectomy. Stroke. 2018;49:1377–85.
Zangerle A, Kiechl S, Spiegel M, Furtner M, Knoflach M, Werner P, et al. Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology. 2007;68:39–44.
Millan M, Remollo S, Quesada H, Renu A, Tomasello A, Minhas P, et al. Vessel patency at 24 hours and its relationship with clinical outcomes and infarct volume in REVASCAT trial (randomized trial of revascularization with solitaire FR device versus best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight hours of symptom onset). Stroke. 2017;48:983–9.
Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285–95.
Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009–18.
Sarraj A, Farrell CM, Reishus K, Sharrief AZ, McCullough L, Savitz SI. Endovascular thrombectomy access in the United States: the current status and an optimization model. In: Paper presented at: International Stroke Conference; 2018; Los Angeles, CA.
Lakomkin N, Dhamoon M, Carroll K, Singh IP, Tuhrim S, Lee J, et al. Prevalence of large vessel occlusion in patients presenting with acute ischemic stroke: a 10-year systematic review of the literature. J Neurointerv Surg. 2019;11:241–5.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Prevention Statistics C and Stroke Statistics S. Heart disease and stroke Statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–e528.
Rai AT, Seldon AE, Boo S, Link PS, Domico JR, Tarabishy AR, et al. A population-based incidence of acute large vessel occlusions and thrombectomy eligible patients indicates significant potential for growth of endovascular stroke therapy in the USA. J Neurointerv Surg. 2017;9:722–6.
McTaggart RA, Yaghi S, Cutting SM, Hemendinger M, Baird GL, Haas RA, et al. Association of a primary stroke center protocol for suspected stroke by large-vessel occlusion with efficiency of care and patient outcomes. JAMA Neurol. 2017;74:793–800.
Ng FC, Low E, Andrew E, Smith K, Campbell BCV, Hand PJ, et al. Deconstruction of interhospital transfer workflow in large vessel occlusion: real-world data in the thrombectomy era. Stroke. 2017;48:1976–9.
Sablot D, Gaillard N, Smadja P, Bonnec JM, Bonafe A. Thrombectomy accessibility after transfer from a primary stroke center: analysis of a three-year prospective registry. Int J Stroke. 2017;12:519–23.
Shah S, Xian Y, Sheng S, Zachrison KS, Saver JL, Sheth KN, et al. Use, temporal trends, and outcomes of endovascular therapy after interhospital transfer in the United States. Circulation. 2019;139:1568–77.
Meretoja A, Keshtkaran M, Tatlisumak T, Donnan GA, Churilov L. Endovascular therapy for ischemic stroke: save a minute-save a week. Neurology. 2017;88:2123–7.
Jahan R, Saver JL, Schwamm LH, Fonarow GC, Liang L, Matsouaka RA, et al. Association between time to treatment with endovascular reperfusion therapy and outcomes in patients with acute ischemic stroke treated in clinical practice. JAMA : the journal of the American Medical Association. 2019;322:252–63.
Holodinsky JK, Patel AB, Thornton J, Kamal N, Jewett LR, Kelly PJ, et al. Drip and ship versus direct to endovascular thrombectomy: the impact of treatment times on transport decision-making. Eur Stroke J. 2018;3:126–35.
Milne MS, Holodinsky JK, Hill MD, Nygren A, Qiu C, Goyal M, et al. Drip ’n ship versus Mothership for endovascular treatment: modeling the best transportation options for optimal outcomes. Stroke. 2017;48:791–4.
Holodinsky JK, Williamson TS, Kamal N, Mayank D, Hill MD, Goyal M. Drip and ship versus direct to comprehensive stroke center: conditional probability modeling. Stroke. 2017;48:233–8.
Prabhakaran S, Ward E, John S, Lopes DK, Chen M, Temes RE, et al. Transfer delay is a major factor limiting the use of intra-arterial treatment in acute ischemic stroke. Stroke. 2011;42:1626–30.
Mohamad NF, Hastrup S, Rasmussen M, Andersen MS, Johnsen SP, Andersen G, et al. Bypassing primary stroke centre reduces delay and improves outcomes for patients with large vessel occlusion. Eur Stroke J. 2016;1:85–92.
Kaminsky AL, Mione G, Omorou Y, Humbertjean L, Bonnerot M, Lacour JC, et al. Outcome of patients with large vessel occlusion stroke after first admission in telestroke spoke versus comprehensive stroke center. J Neurointerv Surg. 2019.
Abilleira S, Perez de la Ossa N, Jimenez X, Cardona P, Cocho D, Purroy F, et al. Transfer to the Local stroke center versus direct transfer to endovascular center of acute stroke patients with suspected large vessel occlusion in the Catalan Territory (RACECAT): study protocol of a cluster randomized within a cohort trial. Int J Stroke. 2019;14:734–44.
Zhao H, Coote S, Easton D, Langenberg F, Stephenson M, Smith K, et al. Melbourne mobile stroke unit and reperfusion therapy: greater clinical impact of thrombectomy than thrombolysis. Stroke. 2020;51:922–30.
Goyal M, Almekhlafi M, Dippel DW, Campbell BCV, Muir K, Demchuk AM, et al. Rapid alteplase administration improves functional outcomes in patients with stroke due to large vessel occlusions. Stroke. 2019;50:645–51.
Chiti A, Giannini N, Terni E, Massimetti G, Gialdini G, Mancuso M, et al. “Cardioembolic profile” in patients with ischemic stroke: data from the analysis of 1037 cases. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2015;24:1287–90.
Ito S, Ueda A, Murate K, Hirota S, Fukui T, Ishikawa T, et al. Differentiation of cancer from atrial fibrillation in patients with acute multifocal stroke. J Neurol Sci. 2016;368:344–8.
Weber R, Nordmeyer H, Hadisurya J, Heddier M, Stauder M, Stracke P, et al. Comparison of outcome and interventional complication rate in patients with acute stroke treated with mechanical thrombectomy with and without bridging thrombolysis. J Neurointerv Surg. 2017;9:229–33.
Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20.
Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol. 2016;15:1138–47.
Kaesmacher J, Bellwald S, Dobrocky T, Meinel TR, Piechowiak EI, Goeldlin M, et al. Safety and efficacy of intra-arterial urokinase after failed, unsuccessful, or incomplete mechanical thrombectomy in anterior circulation large-vessel occlusion stroke. JAMA Neurol. 2019.
Renu A, Blasco J, Millan M, Marti-Fabregas J, Cardona P, Oleaga L, et al. The chemical optimization of cerebral embolectomy trial: study protocol. Int J Stroke. 2019.
Pfefferkorn T, Holtmannspotter M, Patzig M, Bruckmann H, Ottomeyer C, Opherk C, et al. Preceding intravenous thrombolysis facilitates endovascular mechanical recanalization in large intracranial artery occlusion. Int J Stroke. 2012;7:14–8.
Behme D, Kabbasch C, Kowoll A, Dorn F, Liebig T, Weber W, et al. Intravenous thrombolysis facilitates successful recanalization with stent-retriever mechanical thrombectomy in middle cerebral artery occlusions. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2016;25:954–9.
Gamba M, Gilberti N, Premi E, Costa A, Frigerio M, Mardighian D, et al. Intravenous fibrinolysis plus endovascular thrombectomy versus direct endovascular thrombectomy for anterior circulation acute ischemic stroke: clinical and infarct volume results. BMC Neurol. 2019;19:103.
Kass-Hout T, Kass-Hout O, Mokin M, Thesier DM, Yashar P, Orion D, et al. Is bridging with intravenous thrombolysis of any benefit in endovascular therapy for acute ischemic stroke? World Neurosurg. 2014;82:e453–8.
Davalos A, Pereira VM, Chapot R, Bonafe A, Andersson T, Gralla J, et al. Retrospective multicenter study of Solitaire FR for revascularization in the treatment of acute ischemic stroke. Stroke. 2012;43:2699–705.
Chalos V, LeCouffe NE, Uyttenboogaart M, Lingsma HF, Mulder M, Venema E, et al. Endovascular treatment with or without prior intravenous alteplase for acute ischemic stroke. J Am Heart Assoc. 2019;8:e011592.
Broeg-Morvay A, Mordasini P, Bernasconi C, Buhlmann M, Pult F, Arnold M, et al. Direct mechanical intervention versus combined intravenous and mechanical intervention in large artery anterior circulation stroke: a matched-pairs analysis. Stroke. 2016;47:1037–44.
Wang H, Zi W, Hao Y, Yang D, Shi Z, Lin M, et al. Direct endovascular treatment: an alternative for bridging therapy in anterior circulation large-vessel occlusion stroke. Eur J Neurol. 2017;24:935–43.
Bellwald S, Weber R, Dobrocky T, Nordmeyer H, Jung S, Hadisurya J, et al. Direct mechanical intervention versus bridging therapy in stroke patients eligible for intravenous thrombolysis: a pooled analysis of 2 registries. Stroke. 2017;48:3282–8.
Mehta RH, Cox M, Smith EE, Xian Y, Bhatt DL, Fonarow GC, et al. Race/ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke. 2014;45:2263–9.
Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275–82.
Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, et al. Lees KR and investigators S. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372:1303–9.
Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296–306.
Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019–30.
Chen SH, Snelling BM, Sur S, Shah SS, McCarthy DJ, Luther E, et al. Transradial versus transfemoral access for anterior circulation mechanical thrombectomy: comparison of technical and clinical outcomes. J Neurointerv Surg. 2019;11:874–8.
Minnerup J, Wersching H, Teuber A, Wellmann J, Eyding J, Weber R, et al. Outcome after thrombectomy and intravenous thrombolysis in patients with acute ischemic stroke: a prospective observational study. Stroke. 2016;47:1584–92.
Abilleira S, Ribera A, Cardona P, Rubiera M, Lopez-Cancio E, Amaro S, et al. Outcomes after direct thrombectomy or combined intravenous and endovascular treatment are not different. Stroke. 2017;48:375–8.
Goyal N, Tsivgoulis G, Frei D, Turk A, Baxter B, Froehler MT, et al. Comparative safety and efficacy of combined IVT and MT with direct MT in large vessel occlusion. Neurology. 2018;90:e1274–82.
Leker RR, Pikis S, Gomori JM, Cohen JE. Is bridging necessary? A pilot study of bridging versus primary stentriever-based endovascular reperfusion in large anterior circulation strokes. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2015;24:1163–7.
Bourcier R, Alexandre PL, Eugene F, Delasalle-Guyomarch B, Guillon B, Kerleroux B, et al. Is bridging therapy still required in stroke due to carotid artery terminus occlusions? J Neurointerv Surg. 2018;10:625–8.
Choi JH, Im SH, Lee KJ, Koo JS, Kim BS, Shin YS. Comparison of outcomes after mechanical thrombectomy alone or combined with intravenous thrombolysis and mechanical thrombectomy for patients with acute ischemic stroke due to large vessel occlusion. World Neurosurg. 2018;114:e165–72.
Imbarrato G, Bentley J, Gordhan A. Clinical outcomes of endovascular thrombectomy in tissue plasminogen activator versus non-tissue plasminogen activator patients at primary stroke care centers. J Neurosci Rural Pract. 2018;9:240–4.
Balodis A, Radzina M, Miglane E, Rudd A, Millers A, Savlovskis J, et al. Endovascular thrombectomy in anterior circulation stroke and clinical value of bridging with intravenous thrombolysis. Acta Radiol. 2019;60:308–14.
Yang P, Treurniet KM, Zhang L, Zhang Y, Li Z, Xing P, et al. Direct Intra-arterial thrombectomy in order to Revascularize AIS patients with large vessel occlusion Efficiently in Chinese Tertiary hospitals: a Multicenter randomized clinical Trial (DIRECT-MT)-Protocol. Int J Stroke. 2019:1747493019882837.
Anaissie JE, Monlezun DJ, Siegler JE, Waring ED, Dowell LN, Samai AA, et al. Intravenous tissue plasminogen activator for wake-up stroke: a propensity score-matched analysis. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2016;25:2603–9.
Barreto AD, Martin-Schild S, Hallevi H, Morales MM, Abraham AT, Gonzales NR, et al. Thrombolytic therapy for patients who wake-up with stroke. Stroke. 2009;40:827–32.
Manawadu D, Bodla S, Jarosz J, Keep J, Kalra L. A case-controlled comparison of thrombolysis outcomes between wake-up and known time of onset ischemic stroke patients. Stroke. 2013;44:2226–31.
Ma H, BCV C, Parsons MW, Churilov L, Levi CR, Hsu C, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380:1795–803.
Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379:611–22.
Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299–309.
Schwamm LH, Wu O, Song SS, Latour LL, Ford AL, Hsia AW, et al. Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results. Ann Neurol. 2018;83:980–93.
Ringleb P, Bendszus M, Bluhmki E, Donnan G, Eschenfelder C, Fatar M, et al. Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection. Int J Stroke. 2019;14:483–90.
Campbell BCV, Ma H, Ringleb PA, Parsons MW, Churilov L, Bendszus M, et al. Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet. 2019;394:139–47.
BCV C, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378:1573–82.
Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK Part 2 Randomized Clinical Trial. JAMA-J AM MED ASSOC. 2020;323:1257–1265.
MR CLEAN-NO IV. 2019. Available online at https://www.mrclean-noiv.nl/home.html. Accessed 22 June 2020.
Conflict of Interest
Dr. Jovin declares that he has no conflict of interest. Dr. Siegler declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Cerebrovascular Disorders
About this article
Cite this article
Siegler, J.E., Jovin, T.G. Thrombolysis Before Thrombectomy in Acute Large Vessel Occlusion: a Risk/Benefit Assessment and Review of the Evidence. Curr Treat Options Neurol 22, 22 (2020). https://doi.org/10.1007/s11940-020-00633-5
- Bridging therapy